Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (84,549)	$ 71,690
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation, amortization and accretion	2,707	3,097
Stock-based compensation expense	3,763	4,130
Loss on extinguishment of debt	830
Gain on disposal of property and equipment	(24)
Loss on foreign currency translation	12,077	3,035
Gain on purchase commitment	(215)	(1,075)
Interest incurred through borrowings under Sanofi Loan Facility		4,125
Interest on note payable to principal stockholder	2,608	2,172
Warrant issuance cost		653
Change in fair value of warrant liability	(5,488)	(7,879)
Other, net	247	717
Changes in operating assets and liabilities:
Accounts receivable, net	(1,502)	(3,114)
Receivable from Sanofi	30,557
Inventory	(798)	(5,124)
Deferred costs from collaboration		13,539
Deferred costs from commercial product sales	(234)	(279)
Prepaid expenses and other current assets	1,303	(516)
Other assets	166	307
Accounts payable	2,099	(10,288)
Accrued expenses and other current liabilities	2,889	6,575
Deferred sales from collaboration		(17,503)
Deferred payments from collaboration	(187)	(135,056)
Deferred revenue, net	(398)	2,014
Recognized loss on purchase commitments	(648)	3,442
Net cash used in operating activities	(34,797)	(65,338)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment		(1,144)
Net proceeds from sale of asset held for sale	16,651
Proceeds from sale of property and equipment	24	17
Net cash provided by (used in) investing activities	16,675	(1,127)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock		772
Proceeds from direct placement		50,000
Issuance cost associated with direct placement		(2,690)
Principal payments on facility financing obligation	(4,000)	(5,000)
Borrowings on note payable to principal stockholder	19,429
Payment of employment taxes related to vested restricted stock units	(110)	(161)
Net cash provided by financing activities	15,319	42,921
NET DECREASE IN CASH AND CASH EQUIVALENTS	(2,803)	(23,544)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	22,895	59,074
CASH AND CASH EQUIVALENTS, END OF PERIOD	20,092	35,530
SUPPLEMENTAL CASH FLOWS DISCLOSURES:
Interest paid in cash, net of amounts capitalized	6,373	7,198
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Repayment of facility financing obligation through issuance of common stock	11,000
Capitalization of interest on note payable to principal stockholder	10,716
Reclassification of warrant liability to additional paid-in capital	$ 1,893
Reclassification of deferred payments from collaboration to Sanofi Loan Facility and loss share obligation		$ 4,713